First- and second-line treatment strategies for chronic phase CML using tyrosine kinase inhibitors – present status discussed at ASH 2009
In the advent of tyrosine kinase inhibitors (TKIs) it seems that CML has been converted into a chronic, manageable condition for most patients. Although Imatinib is currently still regarded as the standard of care in newly diagnosed patients, second-line TKIs (e.g. nilotinib) strongly add to the therapeutic armamentarium in this setting which could modify the disease management algorithms in the near future. The present report summarizes current developments reported at ASH 2009.